{
    "id": 11668,
    "fullName": "EWSR1 - FLI1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "EWSR1-FLI1 results in the fusion of EWSR1 and FLI1, leading to transformation in cultured cells and altered transcriptional regulatory activity (PMID: 8516324, PMID: 8164678).",
            "references": [
                {
                    "id": 3626,
                    "pubMedId": 8164678,
                    "title": "DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/8164678"
                },
                {
                    "id": 3625,
                    "pubMedId": 8516324,
                    "title": "Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/8516324"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2130,
        "geneSymbol": "EWSR1",
        "terms": [
            "EWSR1",
            "bK984G1.4",
            "EWS",
            "EWS-FLI1"
        ]
    },
    "variant": "EWSR1 - FLI1",
    "createDate": "09/10/2015",
    "updateDate": "03/21/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 2313,
                "geneSymbol": "FLI1",
                "terms": [
                    "FLI1",
                    "BDPLT21",
                    "EWSR2",
                    "SIC-1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 10090,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Rydapt (midostaurin) and Linsitinib (OSI-906) resulted in a synergistic effect in a Ewing sarcoma cell line harboring EWSR1-FLI1 in culture (PMID: 28062706).",
            "molecularProfile": {
                "id": 11727,
                "profileName": "EWSR1 - FLI1"
            },
            "therapy": {
                "id": 5380,
                "therapyName": "Linsitinib + Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8019,
                    "pubMedId": 28062706,
                    "title": "Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28062706"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5472,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YK-4-279 delayed tumor growth in human Ewing's sarcoma cell line xenograft models harboring EWSR1-FLI1 (PMID: 25964201).",
            "molecularProfile": {
                "id": 11727,
                "profileName": "EWSR1 - FLI1"
            },
            "therapy": {
                "id": 3419,
                "therapyName": "YK-4-279",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5072,
                    "pubMedId": 25964201,
                    "title": "An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964201"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10089,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Rydapt (midostaurin) and BMS-754807 resulted in a synergistic effect, demonstrating inhibition of colony formation and increased apoptotic activity in a Ewing sarcoma cell line harboring EWSR1-FLI1 in culture (PMID: 28062706).",
            "molecularProfile": {
                "id": 11727,
                "profileName": "EWSR1 - FLI1"
            },
            "therapy": {
                "id": 5379,
                "therapyName": "BMS-754807 + Midostaurin",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8019,
                    "pubMedId": 28062706,
                    "title": "Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28062706"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4963,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a Ewing's sarcoma cell line harboring EWSR1-FLI1 was sensitive to Istodax (romidepsin) in vitro and in mouse models, resulting in decreased expression of the fusion protein, inhibition of tumor growth, and apoptotic induction (PMID: 15849726).",
            "molecularProfile": {
                "id": 11727,
                "profileName": "EWSR1 - FLI1"
            },
            "therapy": {
                "id": 1075,
                "therapyName": "Romidepsin",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4814,
                    "pubMedId": 15849726,
                    "title": "Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15849726"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9334,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lurbinectedin resulted in decreased activity of EWSR1-FLI1 activity and repression of EWSR1-FLI gene targets in a Ewing sarcoma cell line in culture and prevented tumor growth in xenograft models (PMID: 27697767).",
            "molecularProfile": {
                "id": 11727,
                "profileName": "EWSR1 - FLI1"
            },
            "therapy": {
                "id": 1195,
                "therapyName": "Lurbinectedin",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7097,
                    "pubMedId": 27697767,
                    "title": "Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27697767"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10844,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zejula (niraparib) inhibited Parp activity and EWSR1-FLI1 gene regulation, and synergized with Temodar (temozolomide) to induce complete tumor regression in patient-derived xenograft models of Ewing's sarcoma harboring EWSR1-FLI1 fusion (Mol Cancer Ther 2013;12(11 Suppl):Abstract nr A258).",
            "molecularProfile": {
                "id": 11727,
                "profileName": "EWSR1 - FLI1"
            },
            "therapy": {
                "id": 1437,
                "therapyName": "Niraparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8867,
                    "pubMedId": null,
                    "title": "The PARP inhibitor niraparib demonstrates synergy with chemotherapy in treatment of patient derived Ewing's sarcoma tumorGraft models.",
                    "url": "http://mct.aacrjournals.org/content/12/11_Supplement/A258.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9335,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Lurbinectedin and Camptosar (irinotecan) resulted in greater suppression of EWSR1-FLI1 activity, sustained tumor regression, and improved survival in Ewing sarcoma cell line xenograft models harboring EWSR1-FLI1 (PMID: 27697767).",
            "molecularProfile": {
                "id": 11727,
                "profileName": "EWSR1 - FLI1"
            },
            "therapy": {
                "id": 4979,
                "therapyName": "Irinotecan + Lurbinectedin",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7097,
                    "pubMedId": 27697767,
                    "title": "Lurbinectedin Inactivates the Ewing Sarcoma Oncoprotein EWS-FLI1 by Redistributing It within the Nucleus.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27697767"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5473,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of enzastaurin and YK-4-279 worked synergistically to inhibit growth of Ewing's sarcoma cell lines harboring EWSR1-FLI1 in culture (PMID: 25964201).",
            "molecularProfile": {
                "id": 11727,
                "profileName": "EWSR1 - FLI1"
            },
            "therapy": {
                "id": 3870,
                "therapyName": "Enzastaurin + YK-4-279",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5072,
                    "pubMedId": 25964201,
                    "title": "An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25964201"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7198,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK525762 (I-BET762) inhibited viability of Ewing's sarcoma cell lines harboring EWSR1-FLI1 in culture (PMID: 27259270).",
            "molecularProfile": {
                "id": 11727,
                "profileName": "EWSR1 - FLI1"
            },
            "therapy": {
                "id": 784,
                "therapyName": "GSK525762",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6194,
                    "pubMedId": 27259270,
                    "title": "BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27259270"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4962,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a Ewing's sarcoma cell line harboring EWSR1-FLI1 treated with Farydak (panobinostat) demonstrated both decreased protein levels and altered transcriptional activity of EWSR1-FLI1 (PMID: 26929321).",
            "molecularProfile": {
                "id": 11727,
                "profileName": "EWSR1 - FLI1"
            },
            "therapy": {
                "id": 1080,
                "therapyName": "Panobinostat",
                "synonyms": null
            },
            "indication": {
                "id": 3368,
                "name": "Ewing sarcoma of bone",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4813,
                    "pubMedId": 26929321,
                    "title": "High-throughput small molecule screen identifies inhibitors of aberrant chromatin accessibility.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26929321"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5825,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ewing's sarcoma cells harboring EWSR1-FLI1 were sensitive to JQ1 in culture and in xenograft models, resulting in decreased expression of EWSR1-FLI1, apoptotic induction, and decreased tumor growth (PMID: 26623725).",
            "molecularProfile": {
                "id": 11727,
                "profileName": "EWSR1 - FLI1"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5170,
                    "pubMedId": 26623725,
                    "title": "Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26623725"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7197,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JQ1 inhibited downstream signaling and proliferation of Ewing's sarcoma cell lines harboring EWSR1-FLI1 in culture and inhibited tumor growth in xenograft models (PMID: 27259270).",
            "molecularProfile": {
                "id": 11727,
                "profileName": "EWSR1 - FLI1"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6194,
                    "pubMedId": 27259270,
                    "title": "BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27259270"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10845,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zejula (niraparib) inhibited Parp activity and EWSR1-FLI1 gene regulation, and synergized with Camptosar (irinotecan) to induce complete tumor regression in patient-derived xenograft models of Ewing's sarcoma harboring EWSR1-FLI1 fusion (Mol Cancer Ther 2013;12(11 Suppl):Abstract nr A258).",
            "molecularProfile": {
                "id": 11727,
                "profileName": "EWSR1 - FLI1"
            },
            "therapy": {
                "id": 5659,
                "therapyName": "Irinotecan + Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8867,
                    "pubMedId": null,
                    "title": "The PARP inhibitor niraparib demonstrates synergy with chemotherapy in treatment of patient derived Ewing's sarcoma tumorGraft models.",
                    "url": "http://mct.aacrjournals.org/content/12/11_Supplement/A258.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17679,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "EWSR1-FLI1 fusions aid the diagnosis of Ewing sarcoma (NCCN.org).",
            "molecularProfile": {
                "id": 11727,
                "profileName": "EWSR1 - FLI1"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3369,
                "name": "Ewing sarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4964,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zolinza (vorinostat) induced apotosis of Ewing's sarcoma cells harboring EWSR1-FLI1 (PMID: 17486365, PMID: 24124617).",
            "molecularProfile": {
                "id": 11727,
                "profileName": "EWSR1 - FLI1"
            },
            "therapy": {
                "id": 1077,
                "therapyName": "Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 3368,
                "name": "Ewing sarcoma of bone",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4816,
                    "pubMedId": 17486365,
                    "title": "Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17486365"
                },
                {
                    "id": 4817,
                    "pubMedId": 24124617,
                    "title": "Ewing sarcoma cells secrete EWS/Fli-1 fusion mRNA via microvesicles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24124617"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 11727,
            "profileName": "EWSR1 - FLI1",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34978,
            "profileName": "EWSR1 - FLI1 KDM1A over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}